Approach to the therapy of hypereosinophilic syndromes

被引：14

作者：

Klion, Amy D. ^{[1
]}

机构：

[1] NIAID, NIH, Parasit Dis Lab, Bethesda, MD 20892 USA

来源：

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA | 2007年 / 27卷 / 03期

关键词：

D O I：

10.1016/j.iac.2007.07.006

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

With the introduction of new diagnostic methods and treatment modalities, it has become increasingly clear that hypereosinophilic syndromes (HES) are a heterogeneous group of disorders for which a single approach to treatment is insufficient. This article discusses current treatment modalities for myeloproliferative HES, idiopathic HES, and lymphocytic-variant HES.

引用

页码：551 / +

页数：11

共 26 条

[1]

Buckley L, 2001, ARTHRITIS RHEUM, V44, P1496

[2] INTERFERON-ALPHA TREATMENT OF 6 PATIENTS WITH THE IDIOPATHIC HYPEREOSINOPHILIC-SYNDROME [J].

BUTTERFIELD, JH ;

GLEICH, GJ .

ANNALS OF INTERNAL MEDICINE, 1994, 121 (09) :648-653

[3] HYPEREOSINOPHILIC SYNDROME - ANALYSIS OF 14 CASES WITH REVIEW OF LITERATURE [J].

CHUSID, MJ ;

DALE, DC ;

WEST, BC ;

WOLFF, SM .

MEDICINE, 1975, 54 (01) :1-27

[4] A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].

Cools, J ;

DeAngelo, DJ ;

Gotlib, J ;

Stover, EH ;

Legare, RD ;

Cortes, J ;

Kutok, J ;

Clark, J ;

Galinsky, I ;

Griffin, JD ;

Cross, NCP ;

Tefferi, A ;

Malone, J ;

Alam, R ;

Schrier, SL ;

Schmid, J ;

Rose, M ;

Vandenberghe, P ;

Verhoef, G ;

Boogaerts, M ;

Wlodarska, I ;

Kantarjian, H ;

Marynen, P ;

Coutre, SE ;

Stone, R ;

Gilliland, DG .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214

[5]

Demiroglu H, 1997, BRIT J HAEMATOL, V97, P928

[6] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[7] Anti-interieukin-5 (mepolizumab) therapy for hypereosinophilic syndromes [J].

Garrett, JK ;

Jameson, SC ;

Thomson, B ;

Collins, MH ;

Wagoner, LE ;

Freese, DK ;

Beck, LA ;

Boyce, JA ;

Filipovich, AH ;

Villanueva, JM ;

Sutton, SA ;

Assa'ad, AH ;

Rothenberg, ME .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 113 (01) :115-119

[8] Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophihc syndrome [J].

Klion, AD ;

Law, MA ;

Noel, P ;

Kim, YJ ;

Haverty, TP ;

Nutman, TB .

BLOOD, 2004, 103 (08) :2939-2941

[9] Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome [J].

Klion, AD ;

Robyn, J ;

Akin, C ;

Noel, P ;

Brown, M ;

Law, M ;

Metcalfe, DD ;

Dunbar, C ;

Nutman, TB .

BLOOD, 2004, 103 (02) :473-478

[10] Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness [J].

Klion, AD ;

Noel, P ;

Akin, C ;

Law, MA ;

Gilliland, DG ;

Cools, J ;

Metcalfe, DD ;

Nutman, TB .

BLOOD, 2003, 101 (12) :4660-4666

← 1 2 3 →